Alimera Sciences Inc

Alimera Sciences — Technical Presentation (February 2011)

21 slides from Alimera Sciences's technical presentation, Feb 3, 2011

  1. Slide 1: Selected Data from the FAME Study Webcast

    Alimera Sciences, Inc. Selected Data from the FAME Study Webcast February 3, 2011 1

  2. Slide 2: ILUVIEN Demographics

    ILUVIEN Demographics 2

  3. Slide 3: Patient Disposition

    Patient Disposition Patient Disposition AE, adverse event; FAc, fluocinolone acetonide. 3

  4. Slide 4: Study, Laser, and Off-Protocol Treatments

    Study, Laser, and Off-Protocol Treatments Off-Protocol Treatments Off-Protocol Treatments 4

  5. Slide 5: ILUVIEN Efficacy

    ILUVIEN Efficacy 5

  6. Slide 6: FAME Study Primary Variable

    FAME Study Variable Primary Variable: Difference between treatment and control groups in percentage of patients with improved BCVA from baseline of 15 or more letters on the ETDRS eye chart 6 BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; FAME, Fluocinolone Ac

  7. Slide 7: Trial A Full Analysis Set

    ^15 Letter Increase in BCVA Full Analysis Set - Trial A Full Analysis Set - Trial A Full Analysis Set - Trial A 7

  8. Slide 8: Trial A Full Analysis Set

    ^15 Letter Increase in BCVA Full Analysis Set - Trial A Full Analysis Set - Trial A Full Analysis Set - Trial A 8

  9. Slide 9: Trial B Full Analysis Set

    ^15 Letter Increase in BCVA Full Analysis Set - Trial B Full Analysis Set - Trial B Full Analysis Set - Trial B 9

  10. Slide 10: Trial B Full Analysis Set

    ^15 Letter Increase in BCVA Full Analysis Set - Trial B Full Analysis Set - Trial B Full Analysis Set - Trial B 10

  11. Slide 11: Trials A & B Combined Full Analysis Set

    ^15 Letter Increase in BCVA Full Analysis Set - Trials A & B Combined Full Analysis Set - Trials A & B Combined Full Analysis Set - Trials A & B Combined 11

  12. Slide 12: Trials A & B Combined Full Analysis Set

    ^15 Letter Increase in BCVA Full Analysis Set - Trials A & B Combined Full Analysis Set - Trials A & B Combined Full Analysis Set - Trials A & B Combined 12

  13. Slide 13: Observed Cases - Trials A & B Combined

    ^15 Letter Increase in BCVA Observed Cases - Trials A & B Combined Observed Cases - Trials A & B Combined Observed Cases - Trials A & B Combined 13

  14. Slide 14: Observed Cases - Trials A & B Combined

    ^15 Letter Increase in BCVA Observed Cases - Trials A & B Combined Observed Cases - Trials A & B Combined Observed Cases - Trials A & B Combined 14

  15. Slide 15: ILUVIEN By Lens Status at Baseline

    ^15 Letter Increase in BCVA Full Analysis Set - Trials A & B Combined ILUVIEN By Lens Status at Baseline ILUVIEN By Lens Status at Baseline ILUVIEN By Lens Status at Baseline ILUVIEN By Lens Status at Baseline 15

  16. Slide 16: ILUVIEN By Lens Status at Baseline

    ^15 Letter Increase in BCVA Full Analysis Set - Trials A & B Combined ILUVIEN By Lens Status at Baseline ILUVIEN By Lens Status at Baseline ILUVIEN By Lens Status at Baseline ILUVIEN By Lens Status at Baseline 16

  17. Slide 17: ILUVIEN Safety

    ILUVIEN Safety 17

  18. Slide 18: Cataract Side Effects

    Cataract Side Effects Phakic Patients at Baseline Only Phakic Patients at Baseline Only Phakic Patients at Baseline Only 18

  19. Slide 19: IOP Related Side Effects

    IOP Related Side Effects IOP Related Side Effects 19

  20. Slide 20: Additional Data and Analysis

    Additional Data and Analysis Additional data and analysis of the FAME Study will be presented by Peter Campochiaro, M.D., on February 12, 2011, at 1:40 p.m. at the Angiogenesis, Exudation and Degeneration 2011 Meeting in the Mandarin Oriental Hotel, Miami, FL. 20

  21. Slide 21: Selected Data from the FAME Study Webcast

    Alimera Sciences, Inc. Selected Data from the FAME Study Webcast February 3, 2011 21

Alimera Sciences — Technical Presentation (February 2011) on 6ix